Home › Kidney Cancer (Renal Cell Carcinoma) › NCT05641935

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Multi-Modality Detection of RCC Recurrence Post Ablation

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Previously received cryotherapy or microwave therapy of RCC
* Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy
* Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study
* Be at least 18 years of age
* Be medically stable
* If a female of child-bearing age, must have a negative pregnancy test
* Have signed Informed Consent to participate in the study

Exclusion Criteria:

* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
* Patients with known sensitivities to the components of Lumason

About the study

This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.

What is being tested

• Sulfur Hexafluoride Lipid Microspheres (drug)
• Contrast-Enhanced Ultrasound (procedure)
• Computed Tomography (procedure)
• Magnetic Resonance Imaging (procedure)
• Electronic Health Record Review (other)

Sponsor: john eisenbrey · Participants: 210 · Started: Nov 3, 2022

Contact the study team

• John Eisenbrey, PhD · Phone: 215-503-5188

Official record on ClinicalTrials.gov — NCT05641935

Locations in the U.S.

Conditions

• Kidney Cancer (Renal Cell Carcinoma)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.